FDA & Government News

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Share

  • 1

    Phase 3b TOGETHER-PsO trial involved 274 patients.

  • 2

    Combination of ixekizumab and tirzepatide vs ixekizumab alone.

  • 3

    27% achieved complete skin clearance and weight loss.

  • 4

    Safety profile: mild to moderate adverse effects.

  • 5

    BMI for obesity was defined as ≥30 kg/m².

Original Source(s)

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

  • by Kathryn Wighton

  • February 18, 2026

  • 3 min

Related Content

Does Air Pollution Affect Skin Health?

Large systematic review finds consistent associations across conditions but highlights low certainty driven by bias and study heterogeneity.

Novel Gene Variants May Be Predisposing Factor for Generalized Pustular Psoriasis

Researchers may have uncovered genetic factors linked to the development of generalized pustular psoriasis.

Patient Insights on HRQOL in Chronic GVHD

Explore how cutaneous graft-versus-host disease impacts patients’ quality of life across physical, psychological, and social domains.